INDEMNITY AGREEMENTIndemnity Agreement • September 24th, 2010 • Quark Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between QUARK BIOTECH, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
QUARK PHARMACEUTICALS, INC. WARRANT TO PURCHASE SERIES H PREFERRED STOCKQuark Pharmaceuticals Inc • September 24th, 2010 • Pharmaceutical preparations • California
This Certifies That, for value received, «WarrantHolder», or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from Quark Pharmaceuticals, Inc., a California corporation, with its principal office at 6501 Dumbarton Circle, Fremont, California 94555 (the “Company”) up to «NumberOfShares» shares of the Series H Preferred Stock of the Company (the “Preferred Stock”).
LEASE AGREEMENTLease Agreement • September 24th, 2010 • Quark Pharmaceuticals Inc • Pharmaceutical preparations
THIS “LEASE”, made this 8th day of September, 2006, between JOHN ARRILLAGA, Trustee, or his Successor Trustee, UTA dated 7/20/77 (JOHN ARRILLAGA SURVIVOR’S TRUST) as amended, and RICHARD T. PEERY, Trustee, or his Successor Trustee, UTA dated 7/20/77 (RICHARD T. PEERY SEPARATE PROPERTY TRUST) as amended, hereinafter called Landlord, and QUARK BIOTECH, INC., a California corporation, hereinafter called Tenant.
QUARK BIOTECH, INC. EMPLOYMENT AGREEMENTEmployment Agreement • September 24th, 2010 • Quark Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS EMPLOYMENT AGREEMENT (THE “AGREEMENT”) is dated as of March 9, 2003 by and between Quark Biotech, Inc., a California corporation (the “Company”), and Shai Erlich (the “Employee”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 24th, 2010 • Quark Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS EMPLOYMENT AGREEMENT, effective as of January 1, 2008 (the “Effective Date”), is made by and between Quark Pharmaceuticals, Inc., a California Corporation (the “Company”), and Daniel Zurr (“Executive”).
